Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 2/20 | 0.75 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.75 |
| ▸ | JUN | P05412 | 4/20 | 0.70 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tylophorine SCHEMBL31497488 | 1.00 | HIF1A (0.75) | HIF1AEPAS1JUNEHMT2DRD1 | |
| (S)-Tylophorine SCHEMBL523625 | 1.00 | HIF1A (0.75) | HIF1AEPAS1JUNEHMT2DRD1 | |
| (+/-)-Tylophorine SCHEMBL523626 | 1.00 | HIF1A (0.75) | HIF1AEPAS1JUNEHMT2DRD1 | |
| Tylophorine SCHEMBL30193979 | 1.00 | HIF1A (0.75) | HIF1AEPAS1JUNEHMT2DRD1 | |
| Tylophorine SCHEMBL8977400 | 1.00 | HIF1A (0.75) | HIF1AEPAS1JUNEHMT2DRD1 | |
| (S)-Tylophorine SCHEMBL5610438 | 0.99 | HIF1A (0.73) | HIF1AEPAS1JUNEHMT2 | |
| SCHEMBL13222745 | 0.96 | HIF1A (0.81) | HIF1AEPAS1JUNEHMT2 | |
| SCHEMBL30637462 | 0.96 | HIF1A (0.81) | HIF1AEPAS1JUNEHMT2 | |
| SCHEMBL13222766 | 0.94 | HIF1A (0.80) | HIF1AEPAS1JUNEHMT2 | |
| SCHEMBL13222824 | 0.93 | JUN (0.81) | HIF1AEPAS1JUNDRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| US-11548891-B1 | Quaternary ammonium salts of phenanthroindolizidine and phenanthroquinolizidine alkaloids as hypoxia-targeted anticancer agents | BATTERJEE MEDICAL COLLEGE (SA) | 2023-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11548891-B1 | Quaternary ammonium salts of phenanthroindolizidine and phenanthroquinolizidine alkaloids as hypoxia-targeted anticancer agents | H1-3, H1-4, H1-2 | HIF1A 8/4885EPAS1 1860/4885JUN 2264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.